TY - JOUR
T1 - Percutaneous Alginate Hydrogel Endomyocardial Injection with a Novel Dedicated Catheter Delivery System
T2 - An Animal Feasibility Study
AU - Wang, Bo
AU - Gao, Chao
AU - Lim, Scott
AU - Wang, Rutao
AU - Zhu, Cun Jun
AU - Onuma, Yoshinobu
AU - Wang, Yunbing
AU - Gao, Runlin
AU - Serruys, Patrick W.J.C.
AU - Lee, Randall J.
AU - Tao, Ling
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/8
Y1 - 2024/8
N2 - The objective of this preclinical study was to evaluate the feasibility and safety of transcatheter endocardial alginate hydrogel injection (TEAi) in a large animal model, utilizing the high-stiffness XDROP® alginate hydrogel in combination with the dedicated EndoWings® catheter-based system. All swine (n = 9) successfully underwent TEAi without complications. Acute results from a subset of animals (n = 5) demonstrated the ability of the catheter to access a wide range of endomyocardial areas and achieve consecutive circumferential hydrogel distribution patterns within the mid-left ventricular wall. Histological examinations at 6 months (n = 4) demonstrated that the XDROP® remained localized within the cardiac tissue. In addition, serial echocardiographic imaging showed that XDROP® had no adverse impacts on LV systolic and diastolic functions. In conclusion, this innovative combination technology has the potential to overcome the translational barriers related to alginate hydrogel delivery to the myocardium. Graphical abstract: (Figure presented.)
AB - The objective of this preclinical study was to evaluate the feasibility and safety of transcatheter endocardial alginate hydrogel injection (TEAi) in a large animal model, utilizing the high-stiffness XDROP® alginate hydrogel in combination with the dedicated EndoWings® catheter-based system. All swine (n = 9) successfully underwent TEAi without complications. Acute results from a subset of animals (n = 5) demonstrated the ability of the catheter to access a wide range of endomyocardial areas and achieve consecutive circumferential hydrogel distribution patterns within the mid-left ventricular wall. Histological examinations at 6 months (n = 4) demonstrated that the XDROP® remained localized within the cardiac tissue. In addition, serial echocardiographic imaging showed that XDROP® had no adverse impacts on LV systolic and diastolic functions. In conclusion, this innovative combination technology has the potential to overcome the translational barriers related to alginate hydrogel delivery to the myocardium. Graphical abstract: (Figure presented.)
KW - Alginate hydrogel
KW - Biomaterial
KW - Percutaneous treatment
UR - http://www.scopus.com/inward/record.url?scp=85185321155&partnerID=8YFLogxK
U2 - 10.1007/s12265-024-10497-8
DO - 10.1007/s12265-024-10497-8
M3 - Article
C2 - 38376702
AN - SCOPUS:85185321155
SN - 1937-5387
VL - 17
SP - 842
EP - 850
JO - Journal of Cardiovascular Translational Research
JF - Journal of Cardiovascular Translational Research
IS - 4
ER -